Our data demonstrate the anti-steatotic function of pan PPAR-iMSC-EVs in NASH, as evidenced by improved histological morphology, decreased micro/macro-vesicular steatosis, and reduced lipid deposits in liver from pan PPAR-iMSC-EVs mice (Fig. 3). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.